The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 02, 2018

Filed:

Mar. 23, 2016
Applicant:

Mayo Foundation for Medical Education and Research, Rochester, MN (US);

Inventors:

Sasantha J. Sangaralingham, Rochester, MN (US);

John C. Burnett, Jr., Rochester, MN (US);

Alessandro Cataliotti, Rochester, MN (US);

Denise M. Heublein, Altura, MN (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/00 (2006.01); C07K 7/14 (2006.01); A61K 38/22 (2006.01); G01N 33/68 (2006.01); C07K 14/58 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
G01N 33/6893 (2013.01); A61K 38/2242 (2013.01); A61K 45/06 (2013.01); C07K 14/58 (2013.01); G01N 2333/58 (2013.01); G01N 2800/04 (2013.01); G01N 2800/042 (2013.01); G01N 2800/32 (2013.01); G01N 2800/324 (2013.01); G01N 2800/325 (2013.01); G01N 2800/347 (2013.01); G01N 2800/52 (2013.01); G01N 2800/56 (2013.01);
Abstract

This document provides methods and materials involved in assessing renal structural alterations (e.g., renal fibrosis, glomerular basement thickening, mesangial matrix expansion, swollen podocytes, and foot processes effacement) as well as methods and materials involved in assessing outcomes. For example, methods and materials for using the level of urinary CNP (e.g., a urinary to plasma CNP ratio) to determine whether or not a mammal is developing renal structural alterations (e.g., renal fibrosis, glomerular basement thickening, mesangial matrix expansion, swollen podocytes, and foot processes effacement) as well as methods and materials for using the level of urinary CNP levels to identify patients having an increased likelihood of experiencing a poor outcome are provided.


Find Patent Forward Citations

Loading…